CHDI

CHDI Inc., a not-for profit organization pursuing a biotech approach to finding therapies for Huntington's Disease, has chosen Evotec as a strategic partner for helping them advance its drug discovery programs.

Since March 2006, Evotec and CHDI have a number of agreements covering medicinal chemistry, assay development and medium-throughput screening (MTS), ultra-high-throughput screening (uHTS) and library synthesis and management services. These contracts cover most of Evotec's integrated discovery offering. With access to these resources, CHDI has all the tools in place to rapidly discover novel drugs against Huntington's Disease targets and further optimize them to the point of clinical development.

14 Jan 2010
Evotec and CHDI Foundation, Inc. Extend Collaboration to Fight Huntington's Disease

14 Feb 2008
Evotec Extends Ongoing Collaboration With CHDI Worth up to US$ 37 Million

10 Aug 2006
CHDI Selects Evotec as Strategic Drug Discovery Partner in the Search for Huntington Disease Treatments

Further Information

Integrated Services.pdf
(pdf - 56,68 kB)

Assay Development & Screening.pdf
(pdf - 520,11 kB)

Fragment-based Drug Discovery.pdf
(pdf - 876,2 kB)

Medicinal Chemistry and Early Develop...
(pdf - 90,85 kB)

ADMET & Zebrafish Screening.pdf
(pdf - 75,19 kB)

Alliances & Projects

Request Information

CHDI

Further Information